Novo Nordisks oral semaglutide 25 mg (Wegovy in a pill*) delivered 16.6% weight loss in people with obesity in a newly published study
Oral semaglutide 25 mg (the once-daily pill formulation of Wegovy®) achieved significant…
People taking Novo Nordisks Wegovy experienced reduced food noise and boosted mental well-being
Results from a real-world survey suggest that semaglutide for weight management (Wegovy®)…
TrimIQ Weight Loss: Official launched in UK and Ireland With Green Tea Probiotic Complex
New York City, NY, Aug. 02, 2025 (GLOBE NEWSWIRE) -- TrimIQ UK,…
Pink Salt Trick Recipe to Weight Loss Trend 2025: An Analysis of Slumber Slim as a Science Informed Option
Albany, New York, July 26, 2025 (GLOBE NEWSWIRE) -- An internet-viral pink…
Fat Burner For Men Launched Over the Counter in USA PhenQ Medically Accredited Thermogenic Fat Burning Supplement for Men
Glasgow, UK, July 13, 2025 (GLOBE NEWSWIRE) -- Introduction: Why PhenQ Is…
Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of Medicine
Data presented simultaneously at the American Diabetes Association’s® 85th Scientific Sessions, showed…
Nixol Capsules Launch in the UK: A Natural Path to Weight Management and Metabolic Support
New York City, June 21, 2025 (GLOBE NEWSWIRE) -- Nixol, a plant-powered…
Novo Nordisk: Higher dose of Wegovy provided average weight loss of 21% in people with obesity with a third achieving 25% or more according to data presented at ADA
Higher dose of Wegovy® provided average weight loss of 21% in people…
Novo Nordisks subcutaneous and oral amycretin data published in The Lancet and presented at ADA 2025
Subcutaneous amycretin phase 1b/2a data on the safety, tolerability and weight loss…
HealthRX Expands Telehealth Website Experience to Include GLP-1 Weight Loss Solutions, Prescription Access, and 24/7 Wellness Support
BROOKLYN, June 19, 2025 (GLOBE NEWSWIRE) -- HealthRX, a digital health platform…